Research Analysts’ Weekly Ratings Updates for Leidos (LDOS)

Several brokerages have updated their recommendations and price targets on shares of Leidos (NYSE: LDOS) in the last few weeks:

• 8/17/2026 – Leidos was given a new $165.00 price target by Wells Fargo & Company.
• 8/12/2026 – Leidos had its price target lowered by The Goldman Sachs Group, Inc. from $152.00 to $132.00. They now have a “neutral” rating on the stock.
• 8/11/2026 – Leidos had its price target raised by Citigroup Inc. from $138.00 to $161.00. They now have a “buy” rating on the stock.
• 8/9/2026 – Leidos had its “hold” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $145.00 price target on the stock.
• 8/7/2026 – Leidos had its price target raised by TD Cowen from $115.00 to $135.00. They now have a “hold” rating on the stock.
• 8/5/2026 – Leidos was given a new $150.00 price target by Robert W. Baird.
• 8/5/2026 – Leidos had its price target lowered by Royal Bank Of Canada from $180.00 to $170.00. They now have an “outperform” rating on the stock.
• 8/5/2026 – Leidos had its price target raised by UBS Group AG from $124.00 to $138.00. They now have a “neutral” rating on the stock.
• 8/5/2026 – Leidos had its price target raised by BNP Paribas Exane from $165.00 to $175.00. They now have an “outperform” rating on the stock.
• 7/16/2026 – Leidos was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/14/2026 – Leidos had its price target lowered by The Goldman Sachs Group, Inc. from $171.00 to $152.00. They now have a “neutral” rating on the stock.
• 7/13/2026 – Leidos had its price target lowered by JPMorgan Chase & Co. from $210.00 to $160.00. They now have an “overweight” rating on the stock.
• 7/10/2026 – Leidos had its price target lowered by Truist Financial Corporation from $195.00 to $160.00. They now have a “buy” rating on the stock.
• 7/8/2026 – Leidos was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/7/2026 – Leidos had its price target lowered by TD Cowen from $160.00 to $115.00. They now have a “hold” rating on the stock.
• 7/1/2026 – Leidos had its price target lowered by Jefferies Financial Group Inc. from $140.00 to $110.00. They now have a “hold” rating on the stock.
• 7/1/2026 – Leidos had its price target lowered by Citigroup Inc. from $178.00 to $138.00. They now have a “buy” rating on the stock.
• 6/30/2026 – Leidos was upgraded by Wall Street Zen from “hold” to “buy”.

Leidos Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Leidos’s dividend payout ratio is currently 16.04%.

Insider Buying and Selling at Leidos

In related news, Director Noel B. Geer sold 10,000 shares of Leidos stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $140.66, for a total value of $1,406,600.00. Following the completion of the sale, the director owned 34,274 shares of the company’s stock, valued at approximately $4,820,980.84. This trade represents a 22.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.77% of the company’s stock.

Leidos is an American technology and engineering company that provides services and solutions to government and commercial customers, with a strong focus on national security, defense, intelligence, and civil government markets. The company delivers systems integration, engineering, cybersecurity, software development, data analytics, cloud migration and managed IT services, as well as mission support for complex programs. Leidos’ work spans areas such as C4ISR (command, control, communications, computers, intelligence, surveillance and reconnaissance), secure communications, sensors and systems engineering, and health IT solutions for public-sector healthcare programs.

Leidos traces its corporate roots to Science Applications International Corporation (SAIC) and emerged as an independent, publicly traded company following a corporate separation in 2013.